PARP Inhibitors in the Management of Ovarian Cancer
Key Points
Key Points
- These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
- The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.
Treatment
...atment
...ting PARPi...
...on 1.0Repeating PARPi therapy in the treatment...
...wly Diagnosed Ovarian Cancer
...ion 2.0PARPi are NOT recommended for use...
Rapid Update – Recommendation 2....
Recommendation 2.2The addition of olaparib to beva...
...commendation 2.3Inclusion of the PARP...
...ian Cancer - Second-line or Greater...
...apid Update – Recommendation 3.0...
...rapy maintenance (second-line or more) ma...
...tment with niraparib for patients w...
...e – Recommendation 3.1/3.2PARPi monotherapy...
...Recommendation 3.3PARPi monotherapy is NOT recom...
PARPi in Combi...
...tion 4.0PARPi are NOT recommended for use in...
...agement of Adverse Events...
...ommendation 5.0 Anemia
...tients requiring a blood transfusion for sympto...
...atients with progressive anemia may be...
...tion 5.1 Neutropenia:...
...factor is NOT indicated for use in patients re...
...(grade 4 lasting at least 5–7 days or asso...
...mendation 5.2 Platelets...
...openia is most common with niraparib. Ni...
...continue PARPi for persistent thrombocytope...
...dation 5.3 Persistent cytopenia:Evalua...
...ndation 5.4 Nausea:...
...will have tachyphylaxis of nausea sy...
.... Persistent nausea requiring daily anti-e...
...hibitors in the Management of Ovar...
...1. PARPi Use Opportunities in PARPi-Naïve Women...